Actively Recruiting
PROfiling Based Endometrial Cancer Adjuvant Therapy
Led by Women's Hospital School Of Medicine Zhejiang University · Updated on 2025-04-01
590
Participants Needed
10
Research Sites
257 weeks
Total Duration
On this page
Sponsors
W
Women's Hospital School Of Medicine Zhejiang University
Lead Sponsor
T
Tongji Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.
CONDITIONS
Official Title
PROfiling Based Endometrial Cancer Adjuvant Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Surgery consisting of total abdominal or laparoscopic hysterectomy, bilateral salpingectomy, pelvic lymphadenectomy or sentinel lymph node mapping and dissection, with or without para-aortic lymphadenectomy, and oophorectomy
- Histologically confirmed endometrioid type endometrial carcinoma, FIGO 2009 stage I or II with specified stage and grade combinations (Stage IA grade 3, Stage IB grade 1 or 2, Stage IB grade 3, Stage II)
- World Health Organization performance status 0-2
- Written informed consent provided
You will not qualify if you...
- Presence of residual disease after surgery
- Any other stage and type of endometrial carcinoma besides specified inclusion
- Histological types serous carcinoma, clear cell carcinoma (at least 10% if mixed), undifferentiated or neuroendocrine carcinoma
- Uterine sarcoma including carcinosarcoma
- Previous malignancy except non-melanomatous skin cancer
- Previous pelvic radiotherapy
- Expected time from surgery to start of radiotherapy exceeding 8 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Tongji Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, China
Actively Recruiting
2
Qilu Hospital of Shandong University
Jinan, Shandong, China
Actively Recruiting
3
Women's Hospital School of Medicine Zhejiang University
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
4
Peking University Peoples Hospital
Beijing, China
Not Yet Recruiting
5
Xiangya Hospital of Central South University
Changsha, China
Actively Recruiting
6
Sun Yat-Sen University Cancer Hospital
Guangzhou, China
Not Yet Recruiting
7
Ningbo First Hospital
Ningbo, China
Actively Recruiting
8
Ningbo Women and Children's Hospital
Ningbo, China
Actively Recruiting
9
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, China
Not Yet Recruiting
10
Shanghai First Maternity and Infant Hospital
Shanghai, China
Not Yet Recruiting
Research Team
X
Xinyu Wang, MD
CONTACT
Y
Yang Li, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here